Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792965 | PMC |
| http://dx.doi.org/10.3389/fmed.2022.1100846 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial Comment: Targeting Heme in Sickle Cell disease: New Perspectives on Priapism Treatment.
Int Braz J Urol
January 2025
Unidade de Pesquisa Urogenital - Universidade Estadual do Rio de Janeiro - Uerj, Rio de Janeiro, RJ, Brasil.
Transition and Sickle Cell Disease.
Pediatrics
December 2024
University of Colorado School of Medicine, Aurora, Colorado.
Financial Impacts of Paying for Gene Therapy for Sickle Cell Disease Under Alternative Pricing and Financing Mechanisms.
Value Health
November 2024
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA; The National Bureau of Economic Research, Cambridge, MA, USA. Electronic address:
Objectives: This study aims to understand the role of alternative pricing and financing mechanisms on the budget impact for payers and the risks and returns of manufacturers for gene therapies.
Methods: This article uses fundamental economic principles to interpret the implications of alternative pricing mechanisms in terms of the share of value appropriated by the manufacturer and how alternative financing mechanisms alter it. It demonstrates these concepts by studying the financial impacts for a payer and the manufacturer across alternative pricing and financing mechanisms that could be used by the US Centers for Medicare and Medicaid Services to pay for gene therapy for sickle cell disease.
Editor's Note to the letter 'Therapeutic potential of the latest oxygen affinity modifying agent, GBT021601, for treating sickle cell disease is questionable' by Drs. Eaton, Alaimo, Metaferia, Cellmer, Thein and Bunn.
Br J Haematol
December 2024
Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!